These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 15562376)

  • 1. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.
    Smith SR; De Jonge L; Volaufova J; Li Y; Xie H; Bray GA
    Metabolism; 2005 Jan; 54(1):24-32. PubMed ID: 15562376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes.
    Shah PK; Mudaliar S; Chang AR; Aroda V; Andre M; Burke P; Henry RR
    Diabetes Obes Metab; 2011 Jun; 13(6):505-10. PubMed ID: 21272186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
    Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
    Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
    Rajeev SP; Sprung VS; Roberts C; Harrold JA; Halford JC; Stancak A; Boyland EJ; Kemp GJ; Cuthbertson DJ; Wilding JP
    BMJ Open; 2017 Jan; 7(1):e013539. PubMed ID: 28132008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone.
    Kushner RF; Sujak M
    Obesity (Silver Spring); 2009 May; 17(5):1017-22. PubMed ID: 19180065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.
    Bray GA; Smith SR; Banerji MA; Tripathy D; Clement SC; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Musi N; Ratner RE; Schwenke DC; Stentz FB; Reaven PD; DeFronzo RA
    Diabetes Obes Metab; 2013 Oct; 15(10):931-7. PubMed ID: 23551856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE).
    Rajeev SP; Roberts CA; Brown E; Sprung VS; Harrold JA; Halford JCG; Stancak A; Boyland EJ; Kemp GJ; Perry J; Howarth E; Jackson R; Wiemken A; Schwab R; Cuthbertson DJ; Wilding JPH
    Diabetes Obes Metab; 2023 Dec; 25(12):3621-3631. PubMed ID: 37667658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: a randomised, controlled trial in humans.
    Loh RKC; Formosa MF; Eikelis N; Bertovic DA; Anderson MJ; Barwood SA; Nanayakkara S; Cohen ND; La Gerche A; Reutens AT; Yap KS; Barber TW; Lambert GW; Cherk MH; Duffy SJ; Kingwell BA; Carey AL
    Diabetologia; 2018 Jan; 61(1):220-230. PubMed ID: 29046921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    Kodama N; Tahara N; Tahara A; Honda A; Nitta Y; Mizoguchi M; Kaida H; Ishibashi M; Abe T; Ikeda H; Narula J; Fukumoto Y; Yamagishi S; Imaizumi T
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4438-45. PubMed ID: 24030946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypocaloric weight loss.
    Shea MK; Nicklas BJ; Marsh AP; Houston DK; Miller GD; Isom S; Miller ME; Carr JJ; Lyles MF; Harris TB; Kritchevsky SB
    Obesity (Silver Spring); 2011 Aug; 19(8):1636-46. PubMed ID: 21233810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial.
    Grey A; Beckley V; Doyle A; Fenwick S; Horne A; Gamble G; Bolland M
    Eur J Endocrinol; 2012 Jun; 166(6):1087-91. PubMed ID: 22408124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight gain in type 2 diabetes mellitus.
    Jacob AN; Salinas K; Adams-Huet B; Raskin P
    Diabetes Obes Metab; 2007 May; 9(3):386-93. PubMed ID: 17391167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
    Smith RC; Jin H; Li C; Bark N; Shekhar A; Dwivedi S; Mortiere C; Lohr J; Hu Q; Davis JM
    Schizophr Res; 2013 Jan; 143(1):18-24. PubMed ID: 23200554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
    JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    Chiquette E; Ramirez G; Defronzo R
    Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.